Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, reported further developments with Proteonomix’s Joint Venture Company, XGEN Medical LLC (”XGen“) towards implementing operations in the United Arab Emirates (U.A.E.).

Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reported that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors. Scheduled for early October, Mr.

Proteonomix, Inc., (OTCBB:PROT.OB) has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity. X Gen Medical has been established with the intention of conducting business in the global medical marketplace. Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide.

Proteonomix, Inc (OTC BB:PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body.